- IPO date: November 8, 2021
- Denomination: MaaT Pharma
- ISIN code/ticker: FR001263482 / MAAT
- ICB classification: 20103010 – Biotechnology
- Listing market: Euronext Paris regulated market
- Eligible for the PEA and PEA-PME schemes and for the 150-0 B ter scheme of the CGI
- Analysts covering the share:
- KBC Securities: Thomas Vranken & Jeroen Van den Bossche
- Kempen: Ingrid Gafanhao, Suzanne van Voorthuizen & René Wouters
- Portzamparc Groupe BNP Paribas: Mohamed Kaabouni
Building a leading microbiome company in oncology
We are the first company developing microbiome-based drugs listed on the regulated market of Euronext Paris.
Stock information

Board of Directors
Engineering degree Ecole Centrale Paris, MBA from Insead
CFO
PharmD, PhD
Oncology Doctor
Engineering degree from Ecole Centrale Paris
She was formerly HR Director EMEA at Google and HR Director France at AOL.
Chief Corporate and People Operations Officer
Engineer, MBA,
Graduated from HEC Paris and Bocconi University in Milan
Documentation
Regulated information
General Meetings
May, 31, 2022: Annual Combined General Meeting preparatory documents
May 31, 2022: Statutory Auditors Reports (Documents in French only)
March 3, 2022: Combined General Meeting (ordinary & extraordinary)
Provisional financial calendar*
*Indicative calendar could be subject to change.